The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The immunological milieu of oropharyngeal squamous cell carcinoma (OPC) according to HPV and smoking status and its influence on prognosis.
 
Luana Guimaraes de Sousa
Research Funding - Agenus (Inst); Elevar Therapeutics (Inst)
 
Juliana Mota Siqueira
No Relationships to Disclose
 
Daniel McGrail
No Relationships to Disclose
 
Mario Marques-Piubelli
No Relationships to Disclose
 
Felippe Lazar Neto
No Relationships to Disclose
 
Sammy Ferri Borgogno
No Relationships to Disclose
 
Fabio Daumas Nunes
No Relationships to Disclose
 
Leandro Matos
Employment - Johnson & Johnson/Janssen (I)
Speakers' Bureau - MSD
 
Luiz Paulo Kowalski
No Relationships to Disclose
 
Camilla Oliveira Hoff
Leadership - Rede D'Or São Luiz (I)
Stock and Other Ownership Interests - Oncostar (I)
Honoraria - Bayer (I); Lilly (I)
Consulting or Advisory Role - Bayer (I); Lilly (I)
Research Funding - Exelixis (I); Lilly (I); Novartis (I)
 
Hui Dai
No Relationships to Disclose
 
Yoshitsugu Mitani
No Relationships to Disclose
 
Kaiyi Li
No Relationships to Disclose
 
Michelle D. Williams
No Relationships to Disclose
 
Shiaw-Yih Lin
No Relationships to Disclose
 
Adel K. El-Naggar
No Relationships to Disclose
 
Andrew G. Sikora
Consulting or Advisory Role - Roche
Research Funding - Celcuity (Inst)
Patents, Royalties, Other Intellectual Property - Patents filed (Inst)
 
Jared Burks
No Relationships to Disclose
 
Maura L. Gillison
Consulting or Advisory Role - Abbvie; Adaptimmune; Aptitude Health; Axiom Biotechnologies; Bayer; Bicara Therapeutics; Bicara Therapeutics; BioNTech; BioNTech; BioNTech SE; Bristol-Myers Squibb; Bristol-Myers Squibb/Roche; Caladrius Biosciences; Coherus Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; EMD Serono; END Merck; Exelixis; Gilead Sciences; Guidepoint Global; Ipsen; Istari; ITeos Therapeutics; Journal of Clinical Oncology; Kura Oncology; LLX Solutions; LLX Solutions; Merck; Merus; Mirati Therapeutics; Nektar; OncLive; Seagen; Sensei Biotherapeutics; Shattuck Labs; Surface Oncology
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Kura Oncology (Inst); Seagen (Inst)
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Coherus Biosciences; Eisai; Elevar Therapeutics; Labcorp Drug Development; Prelude Therapeutics; Regeneron; Remix Therapeutics; Sanofi/Aventis
Research Funding - Ayala Pharmaceuticals (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year